Welcome to our dedicated page for Doximity SEC filings (Ticker: DOCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Doximity, Inc. (DOCS) SEC filings page provides access to the company’s official regulatory disclosures as a New York Stock Exchange–listed issuer. Doximity files annual, quarterly, and current reports that describe its financial condition, results of operations, governance matters, and material events affecting the business.
In its filings and related press releases, Doximity presents condensed consolidated balance sheets, statements of operations, and statements of cash flows, along with discussions of non-GAAP financial measures. The company explains how it calculates metrics such as non-GAAP gross profit, non-GAAP net income, adjusted EBITDA, and free cash flow, and provides reconciliations to GAAP results. These documents allow readers to see how Doximity evaluates its performance beyond standard accounting measures.
Current reports on Form 8-K for DOCS include items such as quarterly earnings announcements, changes in executive roles, annual meeting voting results, and legal developments. For example, Doximity has filed 8-Ks to furnish earnings press releases, to report the outcomes of its annual meeting of stockholders, to disclose changes in its general counsel and related roles, and to describe a securities litigation settlement agreement that remains subject to court approval and other customary conditions.
Through its proxy materials and related filings, Doximity also reports on corporate governance topics, including the election of directors, ratification of its independent registered public accounting firm, and advisory votes on executive compensation. Voting results, including the participation of Class A and Class B common stock, are detailed in these documents.
On this page, AI-powered tools can summarize lengthy DOCS filings, highlight key sections on revenue trends, profitability, cash flows, and risk disclosures, and surface notable items such as settlement agreements or executive transitions. Users can quickly review quarterly reports, annual reports, and Form 4 and other transaction-related filings, while relying on real-time updates from the SEC’s EDGAR system to follow new disclosures from Doximity, Inc.
Doximity, Inc. interim PFO and PAO Siddharth Sitaram exercised stock options for 5,000 shares of Class B Common Stock at an exercise price of
He then sold 2,319 shares of Class A Common Stock at
Doximity, Inc. interim PFO and PAO Siddharth Sitaram exercised stock options and converted Class B shares into Class A shares, then sold a small portion of stock. He exercised options for 5,000 shares at an exercise price of
He then sold 2,282 shares of Class A Common Stock at
DOCS Rule 144 notice: Morgan Stanley Smith Barney LLC reported a proposed sale of 2,319 Common shares via a stock option exercise for cash on 03/10/2026. The filing lists prior dispositions of 2,282 shares on 02/10/2026 and 2,324 shares on 01/12/2026.
Doximity, Inc. director Kira Scherer Wampler reported several related equity transactions. On March 3, 2026, she exercised a stock option for 2,000 shares at a price of
On the same date, 2,000 shares of Class B Common Stock converted into 2,000 shares of Class A Common Stock at a conversion price of
Also on March 3, 2026, Wampler completed an open-market sale of 2,000 shares of Class A Common Stock at a price of
DOCS reported a proposed sale of 2,000 common shares via a stock option exercise on
It also discloses prior sales by KIRA WAMPLER, including 2,000 shares on
Doximity, Inc. reported that interim PFO and PAO Sitaram Siddharth had several equity transactions in Class A common stock. He received a grant of 9,992 restricted stock units on February 15, 2026, which vest in equal quarterly installments over 33 months beginning on May 15, 2026, contingent on continued service. Each unit represents one share of Class A stock. On the same date, 946 shares were withheld by Doximity to cover tax obligations related to previously granted RSUs, a mandatory withholding rather than a discretionary sale. Siddharth also acquired 384 shares through the 2021 Employee Stock Purchase Plan at a price equal to 85% of the February 15, 2026 closing price, bringing his directly held stake to 78,733 shares of Class A common stock.
Doximity, Inc. Chief Financial Officer Anna Bryson reported two equity-related transactions in Class A Common Stock. She received a grant of 152,258 restricted stock units on February 15, 2026, with each RSU representing one share and vesting in equal quarterly installments over 12 months, subject to continued service.
On the same date, 11,381 shares of Class A Common Stock were withheld at $25.02 per share to satisfy tax-withholding obligations tied to previously granted RSUs. According to the disclosure, this withholding followed a pre-established issuer election and is described as a non-discretionary, tax-related disposition rather than an open-market trade.
Doximity, Inc. Chief Executive Officer Jeffrey Tangney reported a tax-related share disposition involving the company’s Class A Common Stock. On February 15, 2026, 8,243 shares were withheld by Doximity to cover tax obligations tied to vesting restricted stock units previously granted to him.
The filing specifies this was a mandated tax-withholding disposition, not a discretionary trade in the open market. After this withholding, Tangney’s directly held Class A Common Stock position reported in the filing stands at 2,232,810 shares.
Doximity, Inc. officer Sitaram Siddharth filed an initial Form 3 reporting his equity holdings. He directly holds 69,303 shares of Class A Common Stock, including several restricted stock unit (RSU) awards that vest quarterly over 36–48 months starting on May 15, 2023, May 15, 2024, and May 15, 2025, subject to continued service.
He also holds stock options to acquire 93,800 shares of Class B Common Stock at an exercise price of $4.12 per share expiring on December 21, 2030, and 70,000 shares at $8.26 per share expiring on February 15, 2031. Each share of Class B Common Stock is convertible into one share of Class A Common Stock under specified conditions.
Doximity, Inc. reported solid growth for the quarter ended December 31, 2025. Revenue rose to $185.1 million from $168.6 million, while net income declined to $61.6 million from $75.2 million as operating expenses, including stock-based compensation, increased.
For the first nine months, revenue reached $499.5 million and net income was $176.9 million, both higher than a year earlier. The company generated $216.9 million in operating cash flow, held $64.8 million in cash plus $670.3 million in marketable securities, and spent $342.9 million on share repurchases.
Doximity closed the $36.3 million Pathway Medical acquisition, adding AI-based medical technology and goodwill, and ended with 126 customers generating at least $500,000 of trailing 12‑month subscription revenue, accounting for about 84% of revenue. Net revenue retention was 112%, indicating continued expansion within existing customers.